Bax inhibition protects against free fatty acid-induced lysosomal permeabilization

被引:142
作者
Feldstein, Ariel E.
Werneburg, Nathan W.
Li, ZhengZheng
Bronk, Steven F.
Gores, Gregory J.
机构
[1] Mayo Clin, Coll Med, Rochester, MN 55905 USA
[2] Cleveland Clin Fdn, Dept Pediat Gastroenterol & Cell Biol, Cleveland, OH 44195 USA
来源
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY | 2006年 / 290卷 / 06期
关键词
nonalcoholic fatty liver disease; lysosomes; Bax; Bcl-2; family; cathepsin B;
D O I
10.1152/ajpgi.00509.2005
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Lysosomal permeabilization is a key feature of hepatocyte lipotoxicity, yet the mechanisms mediating this critical cellular event are unclear. This study examined the mechanisms involved in free fatty acid (FFA)-induced lysosomal permeabilization and the role of Bax, a Bc1-2 family member, in this event. Exposure of liver cells to palmitate induced Bax activation and translocation to lysosomes. Studies to suppress Bax activation either by pharmacological approaches or small interfering-RNA-mediated inhibition of Bax expression showed that lysosomal permeabilization is Bax dependent. In addition, palmitate treatment resulted in a significant decrease in Bc1-X-L, a Bax antagonist. Moreover, forced Bc1-X-L expression blocked lysosomal permeabilization. Lysosomal permeabilization by FFA was ceramide and caspase independent. Finally, paradigms that inhibit lysosomal permeabilization also reduced apoptosis. In conclusion, these data strongly support a regulatory role for Bax in FFA-mediated lysosomal permeabilization and subsequent cell death.
引用
收藏
页码:G1339 / G1346
页数:8
相关论文
共 39 条
[1]   The natural history of nonalcoholic fatty liver disease: A population-based cohort study [J].
Adams, LA ;
Lymp, JF ;
St Sauver, J ;
Sanderson, SO ;
Lindor, KD ;
Feldstein, A ;
Angulo, P .
GASTROENTEROLOGY, 2005, 129 (01) :113-121
[2]   Nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Wong, Vincent W. -S. ;
Nobili, Valerio ;
Day, Christopher P. ;
Sookoian, Silvia ;
Maher, Jacquelyn J. ;
Bugianesi, Elisabetta ;
Sirlin, Claude B. ;
Neuschwander-Tetri, BrentA. ;
Rinella, Mary E. .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[3]   Molecular mediators of hepatic steatosis and liver injury [J].
Browning, JD ;
Horton, JD .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (02) :147-152
[4]   Pathology of steatohepatitis [J].
Brunt, EM ;
Tiniakos, DG .
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2002, 16 (05) :691-707
[5]   Nonalcoholic fatty liver disease [J].
Clark, JM ;
Brancati, FL ;
Diehl, AM .
GASTROENTEROLOGY, 2002, 122 (06) :1649-1657
[6]   The BCL2 family: Regulators of the cellular life-or-death switch [J].
Cory, S ;
Adams, JM .
NATURE REVIEWS CANCER, 2002, 2 (09) :647-656
[7]  
Day C P, 2002, J Gastroenterol Hepatol, V17 Suppl 3, pS377, DOI 10.1046/j.1440-1746.17.s3.31.x
[8]   Steatohepatitis: A tale of two "hits"? [J].
Day, CP ;
James, OFW .
GASTROENTEROLOGY, 1998, 114 (04) :842-845
[9]   Fatty liver, hypertension, and the metabolic syndrome [J].
Diehl, AM .
GUT, 2004, 53 (07) :923-924
[10]   Apoptosis in alcoholic and nonalcoholic steatohepatitis [J].
Feldstein, AE ;
Gores, GJ .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2005, 10 :3093-3099